TY - JOUR T1 - DEVELOPMENT AND VALIDATION OF AN ENZYME-LINKED IMMUNOASSAY KIT FOR DIAGNOSIS AND SURVEILLANCE OF COVID-19 JF - medRxiv DO - 10.1101/2021.06.23.21259392 SP - 2021.06.23.21259392 AU - Flávia F. Bagno AU - Sarah A. R. Sérgio AU - Maria Marta Figueiredo AU - Lara C. Godoi AU - Luis A. F. Andrade AU - Natália C. Salazar AU - Camila P. Soares AU - Andressa Aguiar AU - Flávia Jaqueline Almeida AU - Edimilson D. da Silva AU - Antônio G. P. Ferreira AU - Edison Luiz Durigon AU - Ricardo T. Gazzinelli AU - Santuza M. R. Teixeira AU - Ana Paula S. M. Fernandes AU - Flavio G. da Fonseca Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/29/2021.06.23.21259392.abstract N2 - There is a massive demand to identify alternative methods to detect new cases of COVID-19 as well as to investigate the epidemiology of the disease. In many countries, importation of commercial kits poses a significant impact on their testing capacity and increases the costs for the public health system. We have developed an ELISA to detect IgG antibodies against SARS-CoV-2 using a recombinant viral nucleocapsid (rN) protein expressed in E. coli. Using a total of 894 clinical samples we showed that the rN-ELISA was able to detect IgG antibodies against SARS-CoV-2 with high sensitivity (97.5%) and specificity (96.3%) when compared to a commercial antibody test. After three external validation studies, we showed that the test accuracy was higher than 90%. The rN-ELISA IgG kit constitutes a convenient and specific method for the large-scale determination of SARS-Cov-2 antibodies in human sera with high reliability.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received funds from CAPES, CNPq, FAPEMIG and from the Brazilian Ministry of Science, Technology and Innovation (MCTI) through the Rede Virus initiative (and its many individual projects). Further funding came from the Instituto Nacional de Ciencia e Tecnologia de Vacinas (INCTV) and from the Minas Gerais Secretary of Health (SES-MG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of sera samples from patients and healthy volunteers was approved by the UFMGs Ethics Committee and by the National Research Ethics Committee (CAAE: 1686320.0.0000.5149).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in the manuscript is freely available. ER -